Standard BioTools Income After Taxes 2010-2024 | LAB
Standard BioTools income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
| Standard BioTools Annual Income After Taxes (Millions of US $) |
|
|---|---|
| 2023 | $-75 |
| 2022 | $-190 |
| 2021 | $-59 |
| 2020 | $-53 |
| 2019 | $-65 |
| 2018 | $-59 |
| 2017 | $-61 |
| 2016 | $-76 |
| 2015 | $-53 |
| 2014 | $-53 |
| 2013 | $-17 |
| 2012 | $-19 |
| 2011 | $-22 |
| 2010 | $-17 |
| 2009 | $-19 |
| Standard BioTools Quarterly Income After Taxes (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-27 |
| 2024-06-30 | $-46 |
| 2024-03-31 | $-32 |
| 2023-12-31 | $-20 |
| 2023-09-30 | $-21 |
| 2023-06-30 | $-17 |
| 2023-03-31 | $-17 |
| 2022-12-31 | $-21 |
| 2022-09-30 | $-29 |
| 2022-06-30 | $-64 |
| 2022-03-31 | $-76 |
| 2021-12-31 | $-9 |
| 2021-09-30 | $-14 |
| 2021-06-30 | $-17 |
| 2021-03-31 | $-19 |
| 2020-12-31 | $-18 |
| 2020-09-30 | $-6 |
| 2020-06-30 | $-13 |
| 2020-03-31 | $-16 |
| 2019-12-31 | $-13 |
| 2019-09-30 | $-13 |
| 2019-06-30 | $-14 |
| 2019-03-31 | $-25 |
| 2018-12-31 | $-15 |
| 2018-09-30 | $-15 |
| 2018-06-30 | $-16 |
| 2018-03-31 | $-13 |
| 2017-12-31 | $-10 |
| 2017-09-30 | $-16 |
| 2017-06-30 | $-17 |
| 2017-03-31 | $-17 |
| 2016-12-31 | $-18 |
| 2016-09-30 | $-20 |
| 2016-06-30 | $-19 |
| 2016-03-31 | $-20 |
| 2015-12-31 | $-13 |
| 2015-09-30 | $-9 |
| 2015-06-30 | $-15 |
| 2015-03-31 | $-16 |
| 2014-12-31 | $-11 |
| 2014-09-30 | $-14 |
| 2014-06-30 | $-13 |
| 2014-03-31 | $-15 |
| 2013-12-31 | $-5 |
| 2013-09-30 | $-4 |
| 2013-06-30 | $-4 |
| 2013-03-31 | $-4 |
| 2012-12-31 | $-4 |
| 2012-09-30 | $-4 |
| 2012-06-30 | $-5 |
| 2012-03-31 | $-7 |
| 2011-12-31 | $-3 |
| 2011-09-30 | $-4 |
| 2011-06-30 | $-7 |
| 2011-03-31 | $-7 |
| 2010-12-31 | $-3 |
| 2010-09-30 | $-3 |
| 2010-06-30 | $-5 |
| 2010-03-31 | $-6 |
| 2009-09-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.588B | $0.106B |
| Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $37.714B | 55.57 |
| Tempus AI (TEM) | United States | $7.994B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $6.961B | 177.00 |
| Inspire Medical Systems (INSP) | United States | $5.693B | 177.56 |
| IRhythm Technologies (IRTC) | United States | $3.453B | 0.00 |
| Privia Health (PRVA) | United States | $2.701B | 225.10 |
| Enovis (ENOV) | United States | $2.693B | 17.94 |
| Azenta (AZTA) | United States | $2.440B | 130.24 |
| Clover Health Investments (CLOV) | United States | $2.230B | 0.00 |
| Omnicell (OMCL) | United States | $2.070B | 67.71 |
| Schrodinger (SDGR) | United States | $1.819B | 0.00 |
| 10x Genomics (TXG) | United States | $1.796B | 0.00 |
| Phreesia (PHR) | United States | $1.669B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.748B | 0.00 |
| Talkspace (TALK) | United States | $0.537B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.515B | 0.00 |
| TruBridge (TBRG) | United States | $0.362B | 105.43 |
| Nyxoah SA (NYXH) | Belgium | $0.354B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.343B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.235B | 0.00 |
| Pulmonx (LUNG) | United States | $0.230B | 0.00 |
| American Well (AMWL) | United States | $0.169B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.096B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.069B | 0.00 |
| CareCloud (CCLD) | United States | $0.058B | 0.00 |
| HeartBeam (BEAT) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.047B | 0.00 |
| Outset Medical (OM) | United States | $0.044B | 0.00 |
| Zepp Health (ZEPP) | China | $0.042B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.042B | 0.00 |
| Zhongchao (ZCMD) | China | $0.035B | 0.00 |
| Movano (MOVE) | United States | $0.034B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.020B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.018B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.012B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.005B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |